Cervarix (TM): a vaccine for the prevention of HPV 16, 18-associated cervical cancer

被引：2
|
作者：
Monie, Archana [1 ]
Hung, Chien-Fu [1 ,2 ]
Roden, Richard [1 ,2 ]
Wu, T-C [1 ,2 ,3 ]
机构：
[1] Johns Hopkins Med Inst, Dept Pathol, Baltimore, MD 21205 USA
[2] Johns Hopkins Med Inst, Dept Obstet & Gynecol, Baltimore, MD 21205 USA
[3] Johns Hopkins Med Inst, Dept Mol Microbiol & Immunol, Baltimore, MD 21205 USA
来源：
BIOLOGICS-TARGETS & THERAPY | 2008年 / 2卷 / 01期
关键词：
HPV; L1; VLP; vaccine; Cervarix;
D O I：
暂无
中图分类号：
R-3 [医学研究方法]; R3 [基础医学];
学科分类号：
1001 ;
摘要：
Cervical cancer continues to be the second largest cause of cancer deaths in women worldwide. Persistent infection with high-risk types of human papillomavirus ( HPV) is a necessary cause of cervical cancer. Thus, prophylactic vaccination against HPV is an attractive strategy to prevent cervical cancer. Current strategies for the development of safe and effective preventive vaccines are based on the induction of neutralizing antibodies against the major capsid protein, L1 of HPV. Cervarix (TM) is one of the preventive HPV vaccines that has been approved in the Europe and Australia and is currently under review by the US Food and Drug Administration. Cervarix is composed of HPV16 and HPV18 L1 virus-like particles (VLPs) formulated in ASO4 adjuvant. Vaccination with Cervarix has been shown to protect women against a high proportion of precursor lesions of cervical cancer caused by these two HPV types. This review explores the various features of this new vaccine candidate and discusses the future directions in the field of HPV vaccine development.
引用
收藏
页码：107 / 113
页数：7
相关论文
共 50 条
  • [11] Clinical update of the AS04-Adjuvanted human Papillomavirus-16/18 cervical cancer vaccine, cervarix®
    Tino F. Schwarz
    Advances in Therapy, 2009, 26 : 983 - 998
  • [12] Polymorphism of the p53 codon 72 arg/pro and the risk of HPV type 16/18-associated cervical and oral cancer in India
    Katiyar, S
    Thelma, BK
    Murthy, NS
    Hedau, S
    Jain, N
    Gopalkrishna, V
    Husain, SA
    Das, BC
    MOLECULAR AND CELLULAR BIOCHEMISTRY, 2003, 252 (1-2) : 117 - 124
  • [13] Polymorphism of the p53 codon 72 arg/pro and the risk of HPV type 16/18-associated cervical and oral cancer in India
    Sanjay Katiyar
    B.K. Thelma
    N.S. Murthy
    Suresh Hedau
    Neeraj Jain
    V. Gopalkrishna
    Syed Akhtar Husain
    Bhudev C. Das
    Molecular and Cellular Biochemistry, 2003, 252 : 117 - 124
  • [14] Efficacy of the bivalent HPV vaccine against HPV 16/18-associated precancer: long-term follow-up results from the Costa Rica Vaccine Trial
    Porras, Carolina
    Tsang, Sabrina H.
    Herrero, Rolando
    Guillen, Diego
    Darragh, Teresa M.
    Stoler, Mark H.
    Hildesheim, Allan
    Wagner, Sarah
    Boland, Joseph
    Lowy, Douglas R.
    Schiller, John T.
    Schiffman, Mark
    Schussler, John
    Gail, Mitchell H.
    Quint, Wim
    Ocampo, Rebeca
    Morales, Jorge
    Rodriguez, Ana C.
    Hu, Shangying
    Sampson, Joshua N.
    Kreimer, Aimee R.
    LANCET ONCOLOGY, 2020, 21 (12): : 1643 - 1652
  • [15] Prevention strategies of cervical cancer in the HPV vaccine era
    Bosch, Xavier
    Harper, Diane
    GYNECOLOGIC ONCOLOGY, 2006, 103 (01) : 21 - 24
  • [16] A Review on the Use of the HPV Vaccine in the Prevention of Cervical Cancer
    Pathak, Pranav
    Pajai, Sandhya
    Kesharwani, Himanshi
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2022, 14 (09)
  • [17] HPV 16/18-associated condyloma acuminatum of the urinary bladder: first international report and review of literature
    Chrisofos, M
    Skolarikos, A
    Lazaris, A
    Bogris, S
    Deliveliotis, C
    INTERNATIONAL JOURNAL OF STD & AIDS, 2004, 15 (12) : 836 - 838
  • [18] Molecular and structural characterization of the L1 virus-like particles that are used as vaccine antigens in Cervarix™, the AS04-adjuvanted HPV-16 and-18 cervical cancer vaccine
    Deschuyteneer, Michel
    Elouahabi, Abdelatif
    Plainchamp, Dominique
    Plisnier, Michel
    Soete, Dominique
    Corazza, Yvon
    Lockman, Laurence
    Giannini, Sandra
    Deschamps, Marguerite
    HUMAN VACCINES, 2010, 6 (05): : 407 - 419
  • [19] HPV vaccine and prevention of cervical cancer. A Contribution to the debate
    Boussageon, Remy
    Ferrat, Emilie
    Flori, Marie
    Erpeldinger, Sylvie
    Maynie-Francois, Christine
    Supper, Irene
    Pouchain, Denis
    EXERCER-LA REVUE FRANCOPHONE DE MEDECINE GENERALE, 2020, (165): : 310 - 314
  • [20] Quadrivalent HPV recombinant vaccine (Gardasil) for the prevention of cervical cancer
    Goeser, Angie L.
    AMERICAN FAMILY PHYSICIAN, 2007, 76 (04) : 573 - 574
12345